Details for Patent: 11,813,266
Which drugs does patent 11,813,266 protect, and when does it expire?
Patent 11,813,266 protects JASCAYD and is included in one NDA.
This patent has thirty-three patent family members in twenty-six countries.
Summary for Patent: 11,813,266
| Title: | Combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) |
| Abstract: | The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Franziska Elena HERRMANN, Peter Nickolaus, Stefan Ludwig Michael WOLLIN |
| Assignee: | Boehringer Ingelheim International GmbH |
| Application Number: | US17/811,914 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Device; Dosage form; |
Drugs Protected by US Patent 11,813,266
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | JASCAYD | nerandomilast | TABLET;ORAL | 218764-001 | Oct 7, 2025 | RX | Yes | No | 11,813,266 | ⤷ Start Trial | TREATMENT OF PROGRESSIVE PULMONARY FIBROSIS IN ADULTS IN COMBINATION WITH NINTEDANIB MONOETHANESULFONATE | ⤷ Start Trial | ||||
| Boehringer Ingelheim | JASCAYD | nerandomilast | TABLET;ORAL | 218764-001 | Oct 7, 2025 | RX | Yes | No | 11,813,266 | ⤷ Start Trial | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS IN ADULTS IN COMBINATION WITH NINTEDANIB MONOETHANESULFONATE | ⤷ Start Trial | ||||
| Boehringer Ingelheim | JASCAYD | nerandomilast | TABLET;ORAL | 218764-002 | Oct 7, 2025 | RX | Yes | Yes | 11,813,266 | ⤷ Start Trial | TREATMENT OF PROGRESSIVE PULMONARY FIBROSIS IN ADULTS IN COMBINATION WITH NINTEDANIB MONOETHANESULFONATE | ⤷ Start Trial | ||||
| Boehringer Ingelheim | JASCAYD | nerandomilast | TABLET;ORAL | 218764-002 | Oct 7, 2025 | RX | Yes | Yes | 11,813,266 | ⤷ Start Trial | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS IN ADULTS IN COMBINATION WITH NINTEDANIB MONOETHANESULFONATE | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,813,266
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018357775 | ⤷ Start Trial | |||
| Australia | 2024203045 | ⤷ Start Trial | |||
| Brazil | 112020003973 | ⤷ Start Trial | |||
| Canada | 3079299 | ⤷ Start Trial | |||
| Chile | 2020000627 | ⤷ Start Trial | |||
| China | 111278442 | ⤷ Start Trial | |||
| Denmark | 3700529 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
